Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Weighted Average and Diluted) (2020 - 2025)

Kymera Therapeutics (KYMR) has disclosed EPS (Weighted Average and Diluted) for 6 consecutive years, with -$0.98 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) fell 10.11% to -$0.98 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.69 through Dec 2025, down 23.83% year-over-year, with the annual reading at -$3.69 for FY2025, 23.83% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.98 at Kymera Therapeutics, down from -$0.94 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was -$0.25 in Q4 2023, with the low at -$0.98 in Q4 2025.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.73, with a median of -$0.71 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 57.63% in 2023, then tumbled 256.0% in 2024.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.67 in 2021, then grew by 11.94% to -$0.59 in 2022, then surged by 57.63% to -$0.25 in 2023, then crashed by 256.0% to -$0.89 in 2024, then dropped by 10.11% to -$0.98 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at -$0.98, -$0.94, and -$0.95 for Q4 2025, Q3 2025, and Q2 2025 respectively.